Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
14 September 2021Website:
http://www.estrellabio.comNext earnings report:
14 February 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 31 min agoDividend
Analysts recommendations
Institutional Ownership
What type of business is Estrella Immunopharma?
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.
What sector is Estrella Immunopharma in?
Estrella Immunopharma is in the Healthcare sector
What industry is Estrella Immunopharma in?
Estrella Immunopharma is in the Biotechnology industry
What country is Estrella Immunopharma from?
Estrella Immunopharma is headquartered in United States
When did Estrella Immunopharma go public?
Estrella Immunopharma initial public offering (IPO) was on 14 September 2021
What is Estrella Immunopharma website?
https://www.estrellabio.com
Is Estrella Immunopharma in the S&P 500?
No, Estrella Immunopharma is not included in the S&P 500 index
Is Estrella Immunopharma in the NASDAQ 100?
No, Estrella Immunopharma is not included in the NASDAQ 100 index
Is Estrella Immunopharma in the Dow Jones?
No, Estrella Immunopharma is not included in the Dow Jones index
When was Estrella Immunopharma the previous earnings report?
No data
When does Estrella Immunopharma earnings report?
The next expected earnings date for Estrella Immunopharma is 14 February 2025